Evaluation of adalimumab effectiveness in anti-tumor necrosis factor-naive pediatric patients with Crohn's disease in clinical practice

被引：0

作者：

Steiner, S. ^{[1
]}

King, E. ^{[2
]}

Park, K. ^{[3
]}

Pashankar, D. ^{[4
]}

Shashidhar, H. ^{[5
]}

Sudel, B. ^{[6
]}

Eichner, S. ^{[7
]}

Chen, S. ^{[2
]}

Pratt, J. ^{[2
]}

Colletti, R. ^{[8
]}

机构：

[1] Indiana Univ Sch Med, Riley Hosp Children, Indianapolis, IN 46202 USA

[2] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA

[3] Stanford Univ, Lucile Salter Packard Childrens Hosp, Palo Alto, CA 94304 USA

[4] Yale New Haven Childrens Hosp, New Haven, CT USA

[5] New Hampshires Hosp Children, Manchester, Lancs, England

[6] Univ Minnesota, Masonic Childrens Hosp, Minneapolis, MN USA

[7] AbbVie, N Chicago, IL USA

[8] Univ Vermont, Childens Hosp, Burlington, VT 05405 USA

[9] ImproveCareNow, Burlington, VT USA

来源：

JOURNAL OF CROHNS & COLITIS | 2017年 / 11卷

关键词：

D O I：

10.1093/ecco-jcc/jjx002.024

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

OP025

引用

下载

页码：S15 / S16

页数：2

共 50 条

[1] EVALUATION OF ADALIMUMAB EFFECTIVENESS IN ANTI-TUMOR NECROSIS FACTOR-NAIVE PEDIATRIC PATIENTS WITH CROHN'S DISEASE IN CLINICAL PRACTICE
Steiner, Steven J.
King, Eileen
Park, K. T.
Pashankar, Dinesh
Shashidhar, Harohalli
Sudel, Boris
Eichner, Samantha
Chen, Shiran
Pratt, Jesse
Colletti, Richard B.
GASTROENTEROLOGY, 2017, 152 (05) : S954 - S955
[2] Clinical, biological, and endoscopic responses to adalimumab in antitumor necrosis factor-naive Crohn's disease: predictors of efficacy in clinical practice
Echarri, Ana
Ollero, Virginia
Barreiro-de Acosta, Manuel
Fernandez-Villaverde, Alberto
Hernandez, Vicent
Lorenzo, Aurelio
Pereira, Santos
Carpio, Daniel
Castro, Javier
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2015, 27 (04) : 430 - 435
[3] Comparative Effectiveness and Safety of Anti-Tumor Necrosis Factor Agents in Biologic-Naive Patients With Crohn's Disease
Singh, Siddharth
Heien, Herbert C.
Sangaralingham, Lindsey R.
Schilz, Stephanie R.
Kappelman, Michael D.
Shah, Nilay D.
Loftus, Edward V., Jr.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2016, 14 (08) : 1120 - +
[4] Infliximab vs adalimumab: Points to consider when selecting anti-tumor necrosis factor agents in pediatric patients with Crohn's disease
Kim, Eun Sil
Kang, Ben
WORLD JOURNAL OF GASTROENTEROLOGY, 2023, 29 (18) : 2784 - 2797
[5] Infliximab vs adalimumab:Points to consider when selecting anti-tumor necrosis factor agents in pediatric patients with Crohn's disease
Eun Sil Kim
Ben Kang
World Journal of Gastroenterology, 2023, (18) : 2784 - 2797
[6] Cost-effectiveness and Clinical Outcomes of Early Anti-Tumor Necrosis Factor-α Intervention in Pediatric Crohn's Disease
Bashir, Naazish S.
Walters, Thomas D.
Griffiths, Anne M.
Ito, Shinya
Ungar, Wendy J.
INFLAMMATORY BOWEL DISEASES, 2020, 26 (08) : 1239 - 1250
[7] Effectiveness and Safety of lmmunomodulators With Anti-Tumor Necrosis Factor Therapy in Crohn's Disease
Osterman, Mark T.
Haynes, Kevin
Delzell, Elizabeth
Zhang, Jie
Bewtra, Meenakshi
Brensinger, Colleen M.
Chen, Lang
Xie, Fenglong
Curtis, Jeffrey R.
Lewis, James D.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2015, 13 (07) : 1293 - +
[8] Adalimumab, a novel anti-tumor necrosis factor-α antibody in a child with refractory Crohn's disease
Mian, S
Baron, H
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2005, 41 (03): : 357 - 359
[9] RADIOGRAPHIC PROGRESSION AND THE EFFECT OF ANTI-TUMOR NECROSIS FACTOR IN CHILDREN WITH TREATMENT NAIVE CROHN'S DISEASE
Scheel, Robert
Geem, Duke
Venkateswaran, Suresh
Pelia, Ranjit S.
Alazraki, Adina
Dillman, Jonathan
Hyams, Jeffrey S.
Denson, Lee A.
Kugathasan, Subra
GASTROENTEROLOGY, 2022, 162 (07) : S428 - S429
[10] Optimizing the use of anti-tumor necrosis factor in the management of patients with Crohn's disease
Nguyen, Douglas L.
Flores, Sarah
Sassi, Kareem
Bechtold, Matthew L.
Nguyen, Emily T.
Parekh, Nimisha K.
THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2015, 6 (03) : 147 - 154

← 1 2 3 4 5 →